SALTIRE-RAAVE: targeting calcific aortic valve disease LDL-density-radius theory

Expert Rev Cardiovasc Ther. 2015 Apr;13(4):355-67. doi: 10.1586/14779072.2015.1025058.

Abstract

SALTIRE and RAAVE were the first two studies to evaluate the use of statin therapy for impeding calcific aortic valve disease (CAVD). This review presents the findings of low-density lipoprotein (LDL)-density-radius theory as tested using the combined results from the SALTIRE and RAAVE studies. Patients who received statin therapy had a greater degree of LDL cholesterol lowering, seen as the % change in LDL (47 vs 2%, p = 0.012), which in itself was significantly associated with a lesser change in aortic valve area (AVA; p < 0.001 and R(2) = 0.27). The percent change in the AVA for the treated patients was 5% and 15% for the nontreated patients (p = 0.579 and R(2) = 0.03). In summary, these published findings suggest that when applying the LDL-density-radius theory, which combines the cellular biology and the hemodynamics as defined by the continuity equation for AVA, there may be a role for lipid-lowering therapy in contemporary patients with calcific aortic valve disease (CAVD).

Keywords: aortic valve stenosis; atherosclerosis; calcification; clinical trials; hemodynamics; statins.

Publication types

  • Review

MeSH terms

  • Aortic Valve / pathology*
  • Aortic Valve Stenosis / blood
  • Aortic Valve Stenosis / drug therapy*
  • Calcinosis / blood
  • Calcinosis / drug therapy*
  • Cholesterol, LDL / blood
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*

Substances

  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors

Supplementary concepts

  • Aortic Valve, Calcification of